Mauna Kea Technologies Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Sacha Loiseau

Chief executive officer

€172.6k

Total compensation

CEO salary percentage	48.6%
CEO tenure	24.3yrs
CEO ownership	n/a
Management average tenure	2.3yrs
Board average tenure	6.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Sacha Loiseau's remuneration changed compared to Mauna Kea Technologies's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2023	n/a	n/a	-€2m
Mar 31 2023	n/a	n/a	-€7m
Dec 31 2022	€173k	€84k	-€11m
Sep 30 2022	n/a	n/a	-€12m
Jun 30 2022	n/a	n/a	-€13m
Mar 31 2022	n/a	n/a	-€13m
Dec 31 2021	€207k	n/a	-€13m
Sep 30 2021	n/a	n/a	-€13m
Jun 30 2021	n/a	n/a	-€13m
Mar 31 2021	n/a	n/a	-€13m
Dec 31 2020	€325k	€156k	-€13m
Sep 30 2020	n/a	n/a	-€13m
Jun 30 2020	n/a	n/a	-€14m
Mar 31 2020	n/a	n/a	-€15m
Dec 31 2019	€252k	€164k	-€15m
Sep 30 2019	n/a	n/a	-€15m
Jun 30 2019	n/a	n/a	-€14m
Mar 31 2019	n/a	n/a	-€13m
Dec 31 2018	€639k	€197k	-€13m
Sep 30 2018	n/a	n/a	-€12m
Jun 30 2018	n/a	n/a	-€11m
Mar 31 2018	n/a	n/a	-€11m
Dec 31 2017	€256k	€205k	-€10m

Compensation vs Market: Sacha's total compensation ($USD184.68K) is below average for companies of similar size in the UK market ($USD346.19K).

Compensation vs Earnings: Sacha's compensation has been consistent with company performance over the past year.

CEO

Sacha Loiseau

24.3yrs

Tenure

€172,636

Compensation

Mr. Alexandre Loiseau, also known as Sacha, Ph.D. has been Chief Executive Officer of Mauna Kea Technologies SA since October 04, 2022. He serves as Venture Partner at Elaia Partners SAS since joining from...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Alexandre Loiseau	Co-Founder	24.3yrs	€172.64k	no data
Come de La Tour du Pin	Chief Financial Officer	less than a year	no data	no data
Nathalie Lecoq	Chief Operating Officer	1.3yrs	no data	no data
Frederic Banegas	Chief Technology Officer	3.3yrs	no data	no data
François Lacombe	Chief Scientific Officer	no data	no data	no data
Daryl Donatelli	Vice President of Global Marketing & U.S. Sales	2.3yrs	no data	no data

2.3yrs

Average Tenure

Experienced Management: 0P5I's management team is considered experienced (2.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Alexandre Loiseau	Co-Founder	12.9yrs	€172.64k	no data
Molly O'Neill	Independent Director	6.3yrs	€19.00k	no data
Christopher McFadden	Independent Director	16.3yrs	€20.00k	no data
Claire Biot	Independent Director	3.8yrs	€15.00k	no data
Jacquelien Ten Dam	Independent Director	3.3yrs	€20.00k	no data

6.3yrs

Average Tenure

Experienced Board: 0P5I's board of directors are considered experienced (6.3 years average tenure).

Mauna Kea Technologies Management

Management criteria checks 4/4

Key information

Recent management updates

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Mauna Kea Technologies SA, Annual General Meeting, Jun 06, 2024

Insufficient new directors

Recent updates

Mauna Kea Technologies SA Provides Sales Guidance for the Year 2024

Insufficient new directors

New minor risk - Financial data availability

No longer forecast to breakeven

Insufficient new directors

No longer forecast to breakeven

Insufficient new directors

Insufficient new directors

Mauna Kea Technologies SA, Annual General Meeting, Jun 06, 2024

Insufficient new directors

Mauna Kea Technologies SA ADR - Sponsored to Be Deleted from OTC Equity

No longer forecast to breakeven

Mauna Kea Technologies SA announced that it expects to receive €6 million in funding from Telix Pharmaceuticals Limited

Mauna Kea Technologies Announces First Patient Enrolled in the Pivotal CLEVER Clinical Trial in Peripheral Lung Cancer

New major risk - Revenue and earnings growth

No longer forecast to breakeven

No longer forecast to breakeven

First half 2023 earnings released: EPS: €0.063 (vs €0.14 loss in 1H 2022)

New major risk - Revenue and earnings growth

No longer forecast to breakeven

Mauna Kea Technologies and Endoscopy Institute of Hawaii Achieve 1,200 Procedure Milestone

Mauna Kea Technologies Appoints Côme de La Tour du Pin as its Chief Financial Officer

Mauna Kea Technologies Announces Start of Enrollment in Peripheral Lung Cancer Multi-Site Clinical Trial Combining Ion® with Cellvizio®

Mauna Kea Technologies SA to Report First Half, 2023 Results on Sep 28, 2023

No longer forecast to breakeven

Mauna Kea Technologies SA Announces the Publication of Results of the First in Human Clinical Study Combining Robotic-Assisted Bronchoscopy and Needle-Based Confocal Laser Endomicroscopy for Lung Cancer

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

Mauna Kea Technologies SA Announces Success of Clinical Trial on Prediction of Remission in Patients with Inflammatory Bowel Disease (IBD) and its Publication in Gastroenterology

Mauna Kea Technologies SA Announces the Appointment of Sacha Loiseau as Chief Executive Officer

Mauna Kea Technologies SA to Report First Half, 2022 Final Results on Oct 20, 2022

Mauna Kea Technologies SA to Report First Half, 2022 Results on Oct 20, 2022

No longer forecast to breakeven

Mauna Kea Technologies Announces First of Its Kind U.S. FDA 510(k) Clearance for Use of Cellvizio in a New Category of Molecular Imaging-guided Endoscopic, Laparoscopic, Needle-Based Procedures

Mauna Kea Technologies SA Announces Start of Enrollment in Peripheral Lung Cancer Multi-Center Clinical Trial

Mauna Kea Technologies SA announced that it has received $12.8 million in funding from Lightspeed China Partners, Qiming Weichuang Venture Capital Management (Shanghai) Company Limited, Shanghai Ivy Investment Holdings Co., Ltd.

First half 2021 earnings released

Mauna Kea Technologies Receives U.S. FDA 510(k) Clearance of its Next-Generation Cellvizio® Platform Combined with a Fluorescent Contrast Agent

Mauna Kea Technologies SA Provides Earnings Guidance for the Twelve Months Ending December 31, 2021

Mauna Kea Technologies Unveils Its Next-Generation Cellvizio® Platform

Full year 2020 earnings released

Mauna Kea Technologies: Cellvizio® Combined with Artificial Intelligence Outperforms Standard of Care for Pancreatic Cyst Diagnosis and Risk Stratification

Mauna Kea Technologies SA to Report Q2, 2021 Results on Jul 22, 2021

Mauna Kea Technologies Announces Board Changes

Telix Pharmaceuticals Limited and Mauna Kea Technologies Announces Exclusive Scientific and Clinical Research Collaboration

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure